PDGFRalpha Inhibitors
3 drugsAbout PDGFRalpha
PDGFR-alpha is a receptor tyrosine kinase crucial for cell growth, differentiation, and survival. Activated by PDGFs, it initiates intracellular signaling cascades that regulate fundamental cellular processes.
PDGFR-alpha is a therapeutic target because of its role in cell proliferation, though there is currently no genetic evidence directly linking it to specific diseases.
PDGFR-alpha is targeted by one FDA-approved small molecule drug, STIVARGA (Bayer), which has three indications.
Top PDGFRalpha Drugs
Bayer is the only company with an approved drug targeting PDGFR-alpha.
The market is highly concentrated, indicating potential entry barriers or limited investment in this target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Full summary • All drugs • Genetic evidence • Trials • Timeline